Gilead's One-Pill HIV Treatment Shows Promise In Late-Stage Trial

benzinga.com/news/health-care/25/11/48845474/gileads-one-pill-hiv-treatment-shows-promise-in-late-stage-trial

Gilead Sciences Inc. (NASDAQ:GILD) on Thursday shared topline results from the Phase 3 ARTISTRY-1 trial.
The open-label trial evaluated the treatment responses of HIV patients who are virologically suppressed switching from a multi-tablet regimen to an investigational single-tablet…

This story appeared on benzinga.com, 2025-11-13 18:55:41.
The Entire Business World on a Single Page. Free to Use →